Neoadjuvant Endocrine Therapy for Estrogen Receptor–Positive Breast Cancer: A Systematic Review and Meta-analysis

Cited by (396)

Items 201–300 of 396

1. Correlation between MRI morphological response patterns and histopathological tumor regression after neoadjuvant endocrine therapy in locally advanced breast cancer: a randomized phase II trial
   Joana Soares Reis, Owen Matthew Truscott Thomas, Maryam Lahooti, Marianne Lyngra, Hossein Schandiz, João Boavida, Kjell‐Inge Gjesdal, Torill Sauer, Jürgen Geisler, Jonn Terje Geitung · 2021 · Breast Cancer Research and Treatment
2. Axillary Response to Neoadjuvant Therapy in Node-Positive, Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Patients: Predictors and Oncologic Outcomes
   Orli Friedman-Eldar, Tolga Özmen, S. James El Haddi, Neha Goel, Youley Tjendra, Susan Beth Kesmodel, Mecker Geraldine Moller, Dido Franceschi, Christina Layton, Eli Avisar · 2022 · Annals of Surgical Oncology
3. Breast cancer gene expression signatures: development and clinical significance—a narrative review
   Siyan Li, Xinmiao Yu, Yingying Xu · 2022 · Translational Breast Cancer Research
4. Efficacy and safety of antibody-drug conjugates in triple-negative and HER-2 positive breast cancer: A systematic review and meta-analysis of clinical trials
   Fatima Afzal, Wajeeha Aiman, Hafsa Zahoor, Ayfa Riaz Bajwa, Syeda Hafsa Kazmi, Aqsa Anwar, Muhammad Yasir Anwar, Sana Rashid, Hina Zubair, Tooba Kashif et al. · 2023 · Breast Disease
5. The tumour response of postmenopausal hormone receptor-positive breast cancers undergoing different types of neoadjuvant therapy: a meta-analysis
   Yaling Wang, Lin He, Yuhua Song, Qian Wu, Haiji Wang, Biyuan Zhang, Xuezhen Ma · 2020 · BMC Women s Health
6. The association between adiposity and anti-proliferative response to neoadjuvant endocrine therapy with letrozole in post-menopausal patients with estrogen receptor positive breast cancer
   Edoardo Isnaldi, François Richard, Maxim De Schepper, Sophia Leduc, Marion Maetens, Tatjana Geukens, Karen Van Baelen, Ha-Linh Nguyen, Ghizlane Rouas, Gabriele M. Zoppoli et al. · 2022 · npj Breast Cancer
7. Geriatric Breast Cancer: Staging, Molecular Surrogates, and Treatment. A Review & Meta-analysis
   Vasco Fonseca, Zacharoula Sidiropoulou · 2023 · Aging and Disease
8. Contemporary Trends in Axillary Surgery for ER-Positive, HER2-Negative Breast Cancer Stratified by Neoadjuvant Endocrine Therapy, Neoadjuvant Chemotherapy, or Upfront Surgery
   Sasha R. Douglas, Samantha Marie Thomas, Akiko Chiba, Maggie Lee DiNome, Gayle A. DiLalla, E. Shelley Hwang, Kendra J. Modell Parrish, Laura Horst Rosenberger, Jennifer Kay Plichta, Ton Wang et al. · 2025 · Annals of Surgical Oncology
9. Integrating traditional biomarkers and emerging predictors to assess neoadjuvant chemotherapy efficacy in breast cancer: a multifactorial analysis of Ki-67, CDK4, EGFR, TILs and ctDNA
   Tianzhao Du, Ye Yuan, Shulan Sun, Zhichao Gao, Xiaoshuai Li · 2024 · BMC Women s Health
10. Clinical efficacy and therapy response prediction of neoadjuvant dalpiciclib plus letrozole in postmenopausal patients with HR+/HER2- stage II-III breast cancer (DARLING 01): a single-arm, open-label, exploratory study
    Lina Zhang, Yueping Liu, Chao Yang, Jie Ma, Yuntao Li, Ruizhen Luo, Jianjun Han, Xiaochun Wang, Zhisheng Zhang, Li Ma et al. · 2025 · Breast Cancer Research
11. Axillary Management and Outcomes After Neoadjuvant Endocrine Therapy in the Randomized PELOPS Trial
    Anna Catherine Weiss, Qingchun Jin, Nabihah Tayob, Eileen Wrabel, Michelle K. DeMeo, Jamie Carter, Michael Constantine, Meredith Gail Faggen, Caroline Cole Block, Mary Anne Fenton et al. · 2025 · Annals of Surgical Oncology
12. Neoadjuvant systemic treatment for breast cancer in Italy: The Italian Society of Surgical Oncology (SICO) Breast Oncoteam survey
    Elisa Vicini, Alessandra Invento, M. Cuoghi, Alberto Bafile, C. Battaglia, Nicoletta Biglia, Massimo Busani, Riccardo Bussone, Ettore Cianchetti, Francesco Caruso et al. · 2018 · European Journal of Surgical Oncology
13. The use of neoadjuvant therapy increases the rate of breast conservation in men with locally advanced breast cancer
    Austin David Williams, Robin M. Ciocca, Jennifer L. Sabol, Ned Z. Carp · 2022 · Clinical Breast Cancer
14. Phase III study of long-term prognosis of estrogen receptor-positive early breast cancer treated with neoadjuvant endocrine therapy with/without adjuvant chemotherapy
    Hiroji Iwata, Yutaka Yamamoto, Takehiko Sakai, Yoshie Hasegawa, Rikiya Nakamura, Hiromitsu Akabane, Shoichiro Ohtani, Masahiro Kashiwaba, Naruto Taira, Tatsuya Toyama et al. · 2023 · Breast Cancer Research and Treatment
15. Neoadjuvant Endocrine Therapy and Delays in Surgery for Ductal Carcinoma in Situ: Implications for the Coronavirus Pandemic
    Austin David Williams, Cecilia Chang, Elin Ruth Sigurdson, Chih-Hsiung Wang, Allison A. Aggon, Maureen V. Hill, Andrea S. Porpiglia, Richard J. Bleicher · 2021 · Annals of Surgical Oncology
16. Combined 70- and 80-gene signatures identify tumors with genomically luminal biology responsive to neoadjuvant endocrine therapy and are prognostic of 5-year outcome in early-stage breast cancer
    James V. Pellicane, Peter D. Beitsch, David T. Rock, Raye J. Budway, Carrie Lynn Dul, Pond R. Kelemen, Andrew Y. Ashikari, Paul L. Baron, Paul D. Weinstein, Angela Marie Mislowsky et al. · 2022 · Surgical Oncology
17. Use of Ultrasound and Ki–67 Proliferation Index to Predict Breast Cancer Tumor Response to Neoadjuvant Endocrine Therapy
    Sean C. Liebscher, Lyndsey J. Kilgore, Onalisa D. Winblad, Nika C. Gloyeske, Kelsey E. Larson, Christa Balanoff, Lauren Elizabeth Nye, Anne P. O’Dea, Priyanka Sharma, Bruce F. Kimler et al. · 2023 · Healthcare
18. A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancer
    Christos Vaklavas, Erica Michelle Stringer-Reasor, Ahmed M. Elkhanany, Kevin J. Ryan, Yufeng Li, Charles P. Theuer, Edward P. Acosta, Shi Wei, Eddy Shih-Hsin Yang, William E. Grizzle et al. · 2023 · Breast Cancer Research and Treatment
19. Neoadjuvant endocrine therapy in ER-positive breast cancer: evolution, indication, and tailored treatment strategy
    Hyehyun Jeong, Sung‐Bae Kim · 2023 · Therapeutic Advances in Medical Oncology
20. When the World Throws You a Curve Ball: Lessons Learned in Breast Cancer Management
    Samilia Obeng‐Gyasi, Charlotte Elizabeth Coles, Jade Jones, Ruth Lauren Sacks, Sara Lightowlers, Judith M. Bliss, Adrian Murray Brunt, Joanne Haviland, Anna M. Kirby, Kevin M. Kalinsky · 2021 · American Society of Clinical Oncology Educational Book
21. Neoadjuvant endocrine therapy often leads to breast and axilla‐conserving surgery in stages II and III hormone receptor‐positive breast cancer patients: A registry study
    Layla Andour, Judith R. Kroep, Hein Putter, Rob A.�E.�M. Tollenaar, Wilma E. Mesker, Marieke Evelien Straver · 2025 · International Journal of Cancer
22. Tailoring neoadjuvant systemic therapy in breast cancer: “The advent of a personalized approach”—The Breast‐Gynecological and Immuno‐Oncology International Cancer Conference (BGICC) consensus and recommendations
    Hesham A. Elghazaly, Hamdy A. Azim, Hope S. Rugo, David Cameron, Sandra M. Swain, Giuseppe Curigliano, Nadia Harbeck, Debu Tripathy, Banu Arun, Matti Aapro et al. · 2024 · Cancer
23. Magnetic resonance imaging insights from active surveillance of women with ductal carcinoma in situ
    Heather I. Greenwood, Cristian K. Maldonado Rodas, Rita I. Freimanis, Alexa Glencer, Phoebe N. Miller, Rita A. Mukhtar, Case E. Brabham, Christina S. F. Yau, Jennifer M. Rosenbluth, Gillian L. Hirst et al. · 2024 · npj Breast Cancer
24. Application status and research progress of targeted therapy drugs for hormone receptor-positive breast cancer
    Han Luo, Yue Sun, Tiefeng Xu · 2025 · Frontiers in Medicine
25. Role of abemaciclib in primary breast cancer: a narrative review of MonarchE
    Nobuyuki Takahashi, Chikako Shimizu, Akihiko Shimomura, Masakazu Toi · 2021 · Translational Breast Cancer Research
26. EZH2 Protein Expression in Estrogen Receptor Positive Invasive Breast Cancer Treated With Neoadjuvant Endocrine Therapy: An Exploratory Study of Association With Tumor Response
    Yujun Gan, Yungtai Lo, Della Makower, Celina Graciela Kleer, Jinyu Lu, Susan Fineberg · 2022 · Applied immunohistochemistry & molecular morphology
27. Correlation between pathologic complete response, event-free survival/disease-free survival and overall survival in neoadjuvant and/or adjuvant HR+/HER2-breast cancer
    Anagha Gogate, Sandip Ranjan, Amit Kumar, Hitesh Bhandari, Eros Papademetriou, Inkyu Kim, Ravi C. Potluri · 2023 · Frontiers in Oncology
28. Differential response to neoadjuvant endocrine therapy for Black/African American and White women in NCDB
    Veronica Jones, Mary Chen Schroeder, Mya L. Roberson, James P. De Andrade, Ingrid Marie Lizarraga · 2023 · Breast Cancer Research and Treatment
29. Morphological and molecular changes of oestrogen receptor‐positive breast cancer following bridging endocrine therapy: a United Kingdom multicentre study
    Islam M. Miligy, Rachna Awasthi, Yasmeen Mir, Anuj Khurana, Vijay S. Sharma, Usha Chandaran, Emad A. Rakha, Yasmine Maurice, Daniel Kearns, Rami Oweis et al. · 2024 · Histopathology
30. The Present and Future of Neoadjuvant Endocrine Therapy for Breast Cancer Treatment
    Covadonga Martí, José Ignacio Sánchez-Méndez · 2021 · Cancers
31. Bridging Endocrine Therapy for HR+/HER2- Resectable Breast Cancer: Is it Safe?
    Kathleen A. Iles, Madeline Thornton, Jihye Park, Mya L. Roberson, Philip M. Spanheimer, David W. Ollila, Kristalyn K. Gallagher · 2021 · The American Surgeon
32. How Does Invasive Breast Cancer Oncotype Dx Recurrence Score on Core Needle Biopsies Influence Neoadjuvant Treatment Decision? A Descriptive Study
    Gahie Nam, Kamaljeet Singh, Mary Lorraine Lopresti, Madhu Micheal Ouseph, Lijuan Wang, Yihong Wang · 2021 · Technology in Cancer Research & Treatment
33. The prevalence and predictors of adjuvant chemotherapy use among patients treated with neoadjuvant endocrine therapy
    Tal Sella, Olga Kantor, Anna Catherine Weiss, Ann H. Partridge, Otto Metzger, Tari A. King · 2022 · Breast Cancer Research and Treatment
34. Quantitative Biomarkers, Genomic Assays, and Demographics Associated with Breast-Conserving Surgery Following Neoadjuvant Therapy in Early-Stage, Hormone Receptor-Positive, HER-Negative Breast Cancer
    Jincong Q. Freeman, Sarah P. Shubeck, Nan Chen, Sudha R. Yarlagadda, Rita Nanda, Dezheng Huo, Frederick Matthew Howard · 2024 · Annals of Surgical Oncology
35. Neoadjuvante Therapie bei Patientinnen mit Mammakarzinom
    Michael Untch, Elmar Stickeler · 2018 · Der Gynäkologe
36. What Is the Role of Neoadjuvant Endocrine Therapy for Breast Cancer?
    Anna Catherine Weiss, Tari A. King · 2022 · Advances in Surgery
37. Les traitements médicaux néoadjuvants des cancers du sein luminaux en 2016
    Paul Henri Cottu · 2016 · Bulletin du Cancer
38. Perinatal Taurine Imbalance Followed by High Sugar Intake Alters the Effects of Estrogen on Renal Excretory Function in Adult Female Rats
    Sanya Roysommuti, Wichaporn Lerdweeraphon, James Michael Wyss · 2017 · Advances in experimental medicine and biology
39. Molecular downstaging: a new paradigm for neoadjuvant endocrine therapy
    Emanuela Ferraro, Monica Nancy Fornier · 2020 · Annals of Translational Medicine
40. Incidence of palliative treatment among breast cancer patients undergoing neoadjuvant therapy: an analysis of the Brazilian public health system
    Ana Maria Fantini Silva, Breno Piva, Marco Antônio Prado Nunes · 2025 · Scientific Reports
41. Long-term survival outcomes of neoadjuvant chemotherapy in stage II-III HR+/HER2- breast cancer
    Jiaxing Liu, Likuan Tan, Hongyu Zhang, Chengzhi Ma, Gang Qin, Shaolong Huang, Long Yang, Feng-hui He, Yao Huang, Miao-Miao Jiao et al. · 2025 · Scientific Reports
42. A foundation model for predicting outcomes of neoadjuvant chemotherapy in breast cancer
    Ruichong Lin, Zifan He, Jingjing Han, Zehua Wang, Yongjian Chen, Luhui Mao, Qing Peng, Zebang Zhang, Tang Li, Zhenjun Huang et al. · 2025 · International Journal of Surgery
43. Neoadjuvant endocrine therapy with sequential palbociclib and chemotherapy based on Ki67 status in stage II-III breast cancer: An open-label, phase II study
    Christina Engebrethsen, Synnøve Yndestad, Mari E. Rasmussen, Emiel A. M. Janssen, Bjørnar Gilje, Egil Støre Blix, Helge Espelid, Steinar Lundgren, Jürgen Geisler, Laura Minsaas et al. · 2025 · The Breast
44. Unchartered waters: Significance of fall in Ki67 index after short-term preoperative endocrine therapy in early breast cancers
    Dhanya Mary Louis, Lakshmi Malavika Nair, Dehannathparambil Kottarathil Vijaykumar, Archana George Vallonthaiel, Jyotsna Yesodharan, Renjitha Bhaskaran, M P Narmadha · 2023 · Breast Disease
45. Effect of Neoadjuvant Hormonal Therapy on Breast Conservation in Invasive Ductal Versus Lobular Carcinoma of the Breast: A Comparative Analysis
    Nicole Hamilton Goldhaber, Thomas J. O'Keefe, Lauren Longo, Sarah L. Blair, Sara M. Grossi · 2025 · Journal of Surgical Oncology
46. Prognostic value of breast MRI characteristics before and during neoadjuvant endocrine therapy in patients with ER+/HER2- breast cancer
    Max A. A. Ragusi, Gonneke A. O. Winter-Warnars, Jelle Wesseling, Sabine C. Linn, Regina G. H. Beets‐Tan, Bas H. M. van der Velden, Sjoerd Geert Elias, Kenneth G. A. Gilhuijs, Claudette E. Loo · 2021 · British Journal of Radiology
47. The effect of prolonged neoadjuvant endocrine therapy on the efficacy of treatment with breast cancer
    Qin Qin, Xu Han, Hui Li, Shui-Ying Zhou, Caihong Wang, Gang-Ling Zhang · 2023 · Technology and Health Care
48. A Research Protocol for a Phase II Single-Arm Clinical Trial Assessing the Feasibility and Efficacy of Neoadjuvant Anastrozole in Patients With Luminal Breast Cancer and Low Proliferative Index: The ANNE Trial
    Carlos Eduardo Paiva, Alinne Tatiane Faria Silva, Izabella da Silva Oliveira, Vitor Souza Guimarães, Domício Carvalho Lacerda, Gustavo Ramos Teixeira, Anapaula Hidemi Uema Watanabe, Nilton Onari, Bianca Sakamoto Ribeiro Paiva, Idam de Oliveira Junior et al. · 2024 · Cancer Control
49. Analysis of primary endocrine therapy in patients older than 70 years with breast cancer rejecting surgery from a single unit in South Africa including COVID-19 issues
    Carol‐Ann Benn, Yastira Ramdas, Teresa Smit, Vernon Shaw, Bernardo Leon Rapoport · 2021 · Journal of Geriatric Oncology
50. Neoadjuvant Chemotherapy for Nonmetastatic Breast Cancer
    Giacomo Montagna, Emanuela Ferraro, Melissa Louise Pilewskie · 2022 · Advances in Oncology
51. Best Practices for Genomic Assay Testing in Early-Stage Breast Cancer: Clinical and Medicolegal Perspectives
    Andrew David Seidman, Darius K. Amjadi, Tammy De La Melena, Darren T. Wheeler · 2016 · Population Health Management
52. Transmembrane 4 L Six Family Member 1 Suppresses Hormone Receptor-–Positive, HER2-Negative Breast Cancer Cell Proliferation
    Jie Chen, Jin Zhu, Shuai‐Jun Xu, Jun Zhou, Xiao-Fei Ding, Yong Liang, Guang Chen, Hongsheng Lu · 2022 · Frontiers in Pharmacology
53. Chronic Aromatase Inhibition Attenuates Synaptic Plasticity in Ovariectomized Mice
    Julia Brill, David J. Linden · 2024 · eNeuro
54. Did the COVID-19 consortium recommendations impact the treatment of breast cancer during the COVID-19 pandemic?
    Marie L. Fefferman, Kelley Chan, Joseph H Cotler, Danielle M. Thompson, Richard J. Bleicher, Scott H. Kurtzman, Jill M. Dietz, Katharine A. Yao · 2025 · Breast Cancer Research and Treatment
55. Perioperative Considerations of Breast Cancer Neoadjuvant Treatments
    Robert P. Brumer, Fernando A. Angarita · 2025 · Clinical Breast Cancer
56. A Review of Current Literature and Real-World Outcomes With Neoadjuvant Chemotherapy in Hormone Receptor Positive, HER2 Negative Breast Cancer
    Gregory L Guzik, Matthew Kurian, Kanchi Patell, Marcus Trybula, Pingfu Fu, Seunghee Park Margevicius, Alberto J. Montero, James Martin · 2025 · Clinical Breast Cancer
57. Neoadjuvant Systemic Therapy Versus Up-Front Surgery in ER +/PR +/HER2- Breast Cancer
    Jamie S. Olapo, Sarah K. Brennan, Sara Hughes Javid, Meghan Rose Flanagan · 2025 · Current Breast Cancer Reports
58. Neoadjuvant Chemotherapy for Nonmetastatic Breast Cancer
    Giacomo Montagna, Emanuela Ferraro, Melissa Louise Pilewskie · 2025 · Hematology/Oncology Clinics of North America
59. Integrative analysis of RNA expression signatures and recurrent genomic alterations before treatment: link to menopausal status, short-term endocrine therapy response and disease-free survival in luminal breast cancer
    G. Zhang, H. Ni, Lidiya Mishieva, Stephan Bartels, Matthias Christgen, Henriette Christgen, Leonie Donata Kandt, Mieke Raap, Ronald Ernest Kates, Oleg Gluz et al. · 2025 · ESMO Open
60. Breaking the shields of resistance: multidimensional therapeutic strategies in the breast cancer drug resistance conundrum
    Zehan Li, Chuzhong Wei, Huazhen Wu, Ziqing Wu, Xiaoli Feng, Fang Bian, Lingxin Zeng, Pingmei Zhang, Qiyu Liao, Ruiming Tang · 2025 · International Journal of Surgery
61. Breast-Conserving Therapy for Multiple Ipsilateral Breast Cancer After Neoadjuvant Systemic Therapy
    Monika K. Masanam, Jennifer Ruth Bellon, José Pablo Leone, Elizabeth Ann Mittendorf, Tari A. King, Olga Kantor · 2026 · Annals of Surgical Oncology
62. Beyond Chemotherapy: Network Meta‐Analysis Reveals Optimal Neoadjuvant Strategies for Luminal Breast Cancer
    Xinyu Li, Peijing Du, Tao Huang · 2026 · Cancer Medicine
63. Medical Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Stage I to III Breast Cancer: ASCO Living Guideline, Version 2026.1.0
    Jennifer Lee Caswell-Jin, Mark R. Somerfield, Muhammad Ali Khan, Gretchen Genevieve Kimmick, Shilpi Gupta, Kara Kenan, Namrata Peswani, Dawn L. Hershman, Brenda J. Ernst, Brittany E. Harvey et al. · 2026 · Journal of Clinical Oncology
64. Towards precision radiation oncology: endocrine therapy response as a biomarker for personalization of breast radiotherapy
    S. M. Nashir Udden, GuemHee Baek, Kamal Pandey, Chantal Vidal, Yulun Liu, Asal Shoushtari Rahimi, D. Nathan Kim, Chika Nwachukwu, Ram Shankar Mani, Prasanna G. Alluri · 2023 · npj Precision Oncology
65. Key points of anti-tumor treatment in breast cancer patients with SARS-CoV-2 infection
    Rui Ge · 2023 · Translational Breast Cancer Research
66. Comparison of neoadjuvant chemotherapy response and prognosis between HR-low/HER2-negative BC and TNBC: an exploratory real-world multicentre cohort study
    Jing Peng, Yue Hong, Qitong Chen, Feng Xu, Danhua Zhang, Jia Yao, Qiongyan Zou, Liqin Yuan, Lun Li, Long Qian et al. · 2024 · Frontiers in Endocrinology
67. Favorable outcome of neoadjuvant endocrine treatment than surgery‐first in female HR ‐positive/ HER2 ‐negative breast cancer patients—A NCDB analysis (2010–2016)
    Peng Xu, Wen Luo, Jingjing Hu, Xiaobin Ma, Qian Hao, Wentao Hui, Zhangjian Zhou, Shuai Lin, Meng Wang, Hao Wu et al. · 2024 · Cancer Medicine
68. The Challenges of Lobular Carcinomas from a Surgeon’s Point of View
    Margit Leonie Hesla Riis · 2024 · Clinical Breast Cancer
69. Potential of epithelial membrane protein 3 as a novel therapeutic target for human breast cancer
    Yi-Wen Wang, Yih-Lin Tuan, Jiu‐Yao Wang, Hong Chang, Chien‐An Chu, Yi‐Lin Chen, Hui‐Wen Chen, Chung‐Liang Ho, Chung‐Ta Lee, Nan-Haw Chow · 2024 · Oncology Reports
70. Molecular characterisation of the residual disease after neoadjuvant endocrine therapy in ER+/HER2- breast cancer uncovers biomarkers of tumour response
    Joanna I. López-Velazco, Sara Manzano, Kepa Elorriaga, María Otaño, Ainhara Lahuerta, Luis Álvarez, Inge Etxabe, Miren Huarte, Elvira Buch, Julia Giménez et al. · 2025 · Translational Oncology
71. Survival outcomes after pathologic complete response with neoadjuvant endocrine therapy vs. neoadjuvant chemotherapy: a retrospective national database study
    Tori C Nierenberg, Samantha Marie Thomas, Ian Halliday, Astrid Botty van den Bruele, Akiko Chiba, Kendra J. Modell Parrish, Hannah E. Woriax, Maggie Lee DiNome, Kelly E. Westbrook, Jennifer Kay Plichta · 2025 · Breast Cancer Research and Treatment
72. Expert review on systemic treatment in the St. Gallen International Breast Cancer Conference 2021
    Mingxi Lin, Yizi Jin, Jian Zhang · 2021 · Translational Breast Cancer Research
73. Tamoxifen for treatment of abnormal uterine bleeding in etonorgstrel implant users: a randomized clinical trial
    Ahmed Nabil Fetih, Ahmed M. Abbas, Fatma A. Kamel, Ihab H. El Nashar · 2019 · International Journal of Reproduction Contraception Obstetrics and Gynecology
74. Empleo actual de la hormonoterapia neoadyuvante en cáncer de mama: resultados de una encuesta realizada en España
    Covadonga Martí Álvarez, Marcos Meléndez, Adolfo Loayza, Elisa Moreno-Palacios, Laura Frías, José Ignacio Sánchez-Méndez · 2020 · Revista de Senología y Patología Mamaria
75. The role of interactomic interactions in tamoxifen-resistant breast cancer: new approaches to searching for the mechanisms of pathogenesis
    M. Yu. Shkurnikov, А. Д. Каприн · 2020 · P A Herzen Journal of Oncology
76. Synchronous Operable Pancreatic and Breast Cancer Without Genetic Mutation: A Literature Review and Discussion
    Adam Ofri, Danika Zuidersma, Connie Irene Diakos, Amanda Gwendolyn Stevanovic, Matthew H. Wong, Samriti Sood, Jaswinder Singh Samra, Anthony James Gill, Anubhav Mittal · 2022 · Frontiers in Surgery
77. Neoadjuvant treatment in solid tumors—the earlier, the better in breast cancer
    Renate Pusch · 2022 · memo - Magazine of European Medical Oncology
78. Risk of metastasis in breast cancer through delay in start of primary therapy
    Kathrin Halfter, Anne Schlesinger‐Raab, G. Schubert-Fritschle, Dieter Hölzel · 2023 · The Lancet Regional Health - Europe
79. Resistance to Resilience: Understanding Post-surgical Hormone Therapy in Breast Cancer Care
    Tanishq Kumar, Rajoshee R Dutta, Swedaj Thakre, Arihant Singh, Vivek R Velagala, Raju Kamlakar Shinde · 2023 · Cureus
80. Local Regional Recurrence Rates Are Low Following Neoadjuvant Endocrine Therapy: What Are the Remaining Barriers to its Widespread Adoption?
    Anna Catherine Weiss, Tari A. King · 2023 · Annals of Surgical Oncology
81. Preoperative Hormone Therapy in the Treatment of Breast Cancer: What Do We Know So Far?
    V. V. Vorotnikov, Пахомова Регина Александровна, A.V. Soinov, A. S. Gunina, Копытич Игорь Викторович, M. G. Tsoi, Абдугаффоров Сардор Абдугаффорович · 2022 · Creative Surgery and Oncology
82. Neoadjuvant Chemotherapy and Endocrine Therapy for Older Patients with Estrogen Receptor Positive Breast Cancer: Comparison of Approaches
    Krislyn N. Miller, Samantha Marie Thomas, Sydney M. Record, Laura Horst Rosenberger, Maggie Lee DiNome, Gayle A. DiLalla, Jeremy Meyer Force, E. Shelley Hwang, Jennifer Kay Plichta · 2023 · Annals of Surgical Oncology
83. Neoadjuvant endocrine therapy for breast cancer: state of the art
    Завьялов Александр Александрович, Тырышкин Александр Игоревич, S.E. Varlamova · 2023 · Practical oncology
84. Optimized treatment strategy for early-stage medium/high-risk hormone receptor-positive/HER2-negative breast cancer
    Zhao Bi, Xiao Sun, Jia-Xian Zhao, Peng Chen, Tianyi Wang, Tong-Yue Ren, Yongsheng Wang · 2024 · International Journal of Surgery
85. A Non-Inferior Randomized Trial of Neoadjuvant Endocrine Therapy Compared to Neoadjuvant Chemotherapy in Premenopausal Patients With Hormone-Responsive and HER2-Negative Lymph Node-Negative Breast Cancer
    Chongshan Gu, Yingjian He, Nan Zhang, Yiqiang Liu, Jinfeng Li, Tianfeng Wang, Tie Fan, Zhaoqing Fan, Tao Ouyang · 2025 · Cancer Control
86. Comparative Efficacy of Neoadjuvant Endocrine Therapy, Neoadjuvant Chemotherapy, and Neoadjuvant Chemo‐Endocrine Therapy in Estrogen Receptor–Positive Breast Cancer Patients: A Meta‐Analysis
    Yi Hua Yuan, Ning Cui, Ziyi Xu, Chang Cui, Zongpeng Zhou, Zhefu Ma · 2025 · The Breast Journal
87. Current concepts and controversies in post-neoadjuvant breast pathology
    Gregory R. Bean, Benjamin C. Calhoun · 2025 · Human Pathology
88. Early Predictive Markers and Histopathological Response to Neoadjuvant Endocrine Therapy in Postmenopausal Patients with HR+/HER2− Early Breast Cancer
    Aleksandra Konieczna, Magdalena Rosinska · 2025 · Cancers
89. Capivasertib cost-effectiveness in treating advanced breast cancer: A US health care perspective
    Chijioke Mmadueke Okeke, Javeria Khalid, James Douglas Thornton, Moosa Tatar · 2025 · Journal of Managed Care & Specialty Pharmacy
90. Neoadjuvant therapy
    Vanessa Castagnaviz, Simon Peter Gampenrieder · 2025 · memo - Magazine of European Medical Oncology
91. MRI-based radiomics model for predicting tumor regression patterns after neoadjuvant chemotherapy in breast cancer
    Lan Wang, Qi Wang, Jun Zhang, Meng Zhang, Tianhui Guo, Wen Gao, Biyuan Zhang, Haiji Wang · 2025 · Frontiers in Medicine
92. Axillary Management after Neoadjuvant Endocrine Therapy (NET)
    Laura D. Leonard, Min Yi, Emma Wingate, Puneet Singh, Abigail Suzanne Caudle, Rosa F. Hwang, Isabelle Bedrosian, Vicente Valero, Jennifer Litton, Nuhad Ibrahim et al. · 2025 · Annals of Surgical Oncology
93. Functional dysconnectivity in breast cancer patients undergoing hormone therapy
    Julie Petersen, Sonya V. Gupta, Alexandra C. Apple, Derin J. Cobia, Mehmet E. Dokucu, Eric Donald Donnelly, William John Gradishar, Marko Mihailovic, James L. Reilly, Joel L. Voss et al. · 2026 · Journal of Clinical and Experimental Neuropsychology
94. Neoadjuvant therapy with an aromatase inhibitor and durvalumab in postmenopausal patients with hormone receptor-positive breast cancer
    Aixa Elena Soyano Muller, Dawn Goodridge, Qianxing Mo, Junmin Whiting, Nazanin Khakpour, Marie Catherine Lee, Christine Laronga, Avan J. Armaghani, Hyo Sook Han, Hatem Soliman et al. · 2026 · Breast Cancer Research and Treatment
95. The Predictive Value of the Tumor‐Stroma Ratio for Neoadjuvant Endocrine Therapy in Hormone Receptor‐Positive Breast Cancer
    Layla Andour, Sophie C. Hagenaars, Anne Florine de Groot, Elly MM Krol-Warmerdam, Judith R. Kroep, Hans Marten Hazelbag, Gerrit‐Jan Liefers, Marieke Evelien Straver, Wilma E. Mesker · 2026 · International Journal of Cancer
96. Effects of short‐course preoperative endocrine therapy on tumour morphology and immunohistochemical profile in oestrogen receptor‐positive, HER2 ‐negative breast cancer
    Claudia Große, A Große, Petar Noack, Caroline Preuß, Heike Kathleen Schwarz, Bruno Schneeweiß, Thomas Gitter, Peter Schrenk, Rupert Langer · 2026 · Histopathology
97. Adjuvante endokrine Therapie des Mammakarzinoms
    Steffi Hartmann, Toralf Reimer, Angrit Stachs · 2016 · Info Onkologie
98. Adjuvante endokrine Therapie des Mammakarzinoms
    Steffi Hartmann, Toralf Reimer, Angrit Stachs · 2017 · gynäkologie + geburtshilfe
99. Pausing for the pandemic? The impact of deferring breast cancer surgery
    Ashlyn E. Whitlock, Benjamin G. Allar, Ted A. James · 2020 · The Breast Journal
100. Evolution of the CDK4/6 inhibitor abemaciclib: from palliative to adjuvant therapy. Clinical experience with abemaciclib in patients with hormone-receptor-positive, HER2-negative breast cancer
     А. Yu. Goryainova, А. I. Stukan, R. A. Murashko, Шаров Сергей Викторович, Е. V. Lymar · 2022 · Meditsinskiy sovet = Medical Council